Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) announced on September 25, 2024, that it granted 3,500 restricted stock units (RSUs) to a new employee on September 23, 2024, under its 2017 Inducement Equity Incentive Plan. This plan is exclusively used for granting equity awards to individuals who were not previously employees or non-employee directors of Esperion, as an inducement for employment, in compliance with NASDAQ Listing Rule 5635(c)(4).
The RSUs will vest as follows: 25% on the one-year anniversary of the recipient's vesting commencement date, and the remaining 75% in twelve equal quarterly installments thereafter, subject to continued employment. The RSUs are governed by the terms and conditions of Esperion's 2017 Inducement Equity Incentive Plan and the RSU agreement covering the grant.
Esperion (NASDAQ: ESPR) ha annunciato il 25 settembre 2024 di aver concesso 3.500 unità azionarie riservate (RSUs) a un nuovo dipendente il 23 settembre 2024, nell'ambito del suo Piano di Incentivazione Azionaria per Induzione del 2017. Questo piano viene utilizzato esclusivamente per concedere premi azionari a individui che non erano precedentemente dipendenti o direttori non dipendenti di Esperion, come incentivo per l'assunzione, in conformità con la Regola di Quotazione NASDAQ 5635(c)(4).
Le RSUs matureranno come segue: 25% alla scadenza di un anno dalla data di inizio di maturazione del beneficiario, e il restante 75% in dodici rate trimestrali uguali successivamente, a condizione di un impiego continuato. Le RSUs sono regolate dai termini e dalle condizioni del Piano di Incentivazione Azionaria per Induzione del 2017 di Esperion e dall'accordo RSU relativo alla concessione.
Esperion (NASDAQ: ESPR) anunció el 25 de septiembre de 2024 que otorgó 3,500 unidades de acciones restringidas (RSUs) a un nuevo empleado el 23 de septiembre de 2024, bajo su Plan de Incentivos de Capital por Inducción de 2017. Este plan se utiliza exclusivamente para otorgar premios de capital a personas que no eran empleados o directores no empleados anteriores de Esperion, como un incentivo para el empleo, en cumplimiento con la Regla de Cotización 5635(c)(4) de NASDAQ.
Las RSUs se consolidarán de la siguiente manera: 25% en el primer aniversario de la fecha de inicio de la consolidación del beneficiario, y el restante 75% en doce cuotas trimestrales iguales posteriormente, sujeto a empleo continuado. Las RSUs están regidas por los términos y condiciones del Plan de Incentivos de Capital por Inducción de 2017 de Esperion y el acuerdo de RSU relacionado con la concesión.
Esperion (NASDAQ: ESPR)는 2024년 9월 25일에 2024년 9월 23일에 새로운 직원에게 3,500개의 제한적 주식 단위(RSUs)를 부여했다고 발표했습니다. 이는 2017년 유인 주식 보상 계획에 따라 시행된 것입니다. 이 계획은 이전에 Esperion의 직원이나 비직원 이사가 아닌 개인에게 주식 보상 지급을 위해 전적으로 사용되며, NASDAQ 상장 규정 5635(c)(4)에 따라 고용 유인을 제공합니다.
RSU는 다음과 같이 배분됩니다: 수령인의 RSU 시작일의 1주년 기념일에 25%가 발생하며, 나머지 75%는 이후 열 두 개의 동일한 분기별 할부로 지급됩니다, 단 지속적인 고용 조건이 필요합니다. RSU는 Esperion의 2017년 유인 주식 보상 계획과 해당 부여와 관련된 RSU 계약의 조건에 따라 운영됩니다.
Esperion (NASDAQ: ESPR) a annoncé le 25 septembre 2024 avoir accordé 3 500 unités d'actions restreintes (RSUs) à un nouvel employé le 23 septembre 2024, dans le cadre de son Plan d'Incitation en Actions de 2017. Ce plan est utilisé exclusivement pour accorder des récompenses en actions à des personnes qui n'étaient pas auparavant des employés ou des directeurs non employés d'Esperion, comme incitatif à l'embauche, conformément à la Règle de Cotation NASDAQ 5635(c)(4).
Les RSUs seront acquises comme suit : 25 % à l'anniversaire d'un an de la date de début de l'acquisition du bénéficiaire, et les 75 % restants en douze versements trimestriels égaux par la suite, sous réserve d'un emploi continu. Les RSUs sont régies par les termes et conditions du Plan d'Incitation en Actions de 2017 d'Esperion et l'accord RSU concernant la subvention.
Esperion (NASDAQ: ESPR) gab am 25. September 2024 bekannt, dass am 23. September 2024 3.500 eingeschränkte Aktieneinheiten (RSUs) an einen neuen Mitarbeiter gewährt wurden, im Rahmen seines Anreiz-Eigenkapitalplans von 2017. Dieser Plan wird ausschließlich zur Vergabe von Eigenkapitalprämien an Personen verwendet, die zuvor keine Mitarbeiter oder nicht-geschäftsführenden Direktoren von Esperion waren, als Anreiz zur Beschäftigung gemäß der NASDAQ Listungsregel 5635(c)(4).
Die RSUs werden wie folgt fällig: 25% am einjährigen Jubiläum des Beginns der Erdienung des Empfängers und die verbleibenden 75% in zwölf gleichen vierteljährlichen Raten danach, vorbehaltlich eines fortdauernden Arbeitsverhältnisses. Die RSUs unterliegen den Bedingungen und Konditionen von Esperions Anreiz-Eigenkapitalplan von 2017 und dem RSU-Vertrag, der die Gewährung abdeckt.
- Granting of RSUs indicates the company's ability to attract new talent
- Vesting schedule aligns employee interests with long-term company performance
- None.
ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on September 23, 2024, the Company granted one new employee 3,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.
The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Each RSU will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient’s vesting commencement date and will vest and become exercisable as to the remaining 75 percent of the shares in twelve equal quarterly installments at the end of each quarter following such anniversary, in each case, subject to each such employee's continued employment with Esperion on such vesting dates. The RSUs are subject to the terms and conditions of Esperion’s 2017 Inducement Equity Incentive Plan, and the terms and conditions of the RSU agreement covering the grant.
Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
How many restricted stock units (RSUs) did Esperion (ESPR) grant on September 23, 2024?
What is the vesting schedule for the RSUs granted by Esperion (ESPR) on September 23, 2024?
Under which plan did Esperion (ESPR) grant the RSUs announced on September 25, 2024?
What is the purpose of Esperion's (ESPR) 2017 Inducement Equity Incentive Plan?
